Dr. Fogel is a native of Toronto, Canada. After obtaining his Masters of Science degree in Pharmacology from the University of Toronto, he completed medical school, Internal Medicine residency and Gastroenterology fellowship at the same institution. Dr. Fogel did a third-tier, advanced fellowship in therapeutic ERCP in 1996–97 at Indiana University Medical Center. He joined the G.I. faculty the following year, and currently he is a Professor of Medicine in the Department of Medicine at Indiana University. His patient care special interests include prevention of post-ERCP pancreatitis, and he served as senior author on the seminal study which demonstrated the beneficial effect of rectal indomethacin in high-risk patients. He is principal investigator for the Indiana University clinical site in the NIH-sponsored consortium for the study of chronic pancreatitis, diabetes, and pancreatic cancer. He is frequently called upon to present his work and speak at regional, national and international meetings.